UPL Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/7afurvsr7wjw0dcsz6lv6kcd.pdf

Key Takeaways


The Margin Inflection: How It Happened and Why It Decelerates

Mike Frank: "We are sitting on fresh inventory that is at the right level and at a competitive cost, giving us the opportunity to compete aggressively to grow our market share and to expand margins simultaneously."

Guidance Upgrade: What Is and Is Not Priced In

Mike Frank: "Our growth in H2 will be almost exclusively volume-driven. We expect prices to be roughly flat, maybe down like, again, 1% or so in Q3. But overall, in the second half, we expect pricing to be very flat, but volumes to lead the growth for our second half business."

Balance Sheet & Liquidity: The Deleveraging Path


Segment Performance: Where Growth and Margin Came From

SegmentRevenue TrendCommentary
UPL Corp▲ +12% YoYHerbicides strong in NA and LatAm (s-metolachlor, metribuzin, triclopyr); fungicides led by mancozeb; insecticides pressured on Sperto® in Brazil but Feroce® brand driving recovery. Contribution margin expanded 400 bps to 35.1%.
Advanta Seeds▲ +26% YoY14% volume expansion; key contributors: corn in India, LatAm, Indonesia; sunflower in Argentina. EBITDA up 57% on higher volumes. Post-harvest business DECCO integrated in September.
SUPERFORM▬ Steady revenueSuper Specialty business up 18% on contract manufacturing volumes; contribution margin ~25%, up 370 bps on improved mix. EBITDA up 24% with 250 bps margin improvement.
UPL SAS (India CP)▼ –10% YoYLower volumes from unfavorable weather; herbicides particularly impacted. Contribution margin improved ~500 bps; EBITDA margin rose 270 bps to 22.7%.
North America (UPL Corp)▲ +79%Boosted by strong herbicide portfolio (metribuzin, s-metolachlor, glufosinate) and fungicides like mancozeb.
Latin America (UPL Corp)▲ +10%Brazil robust, Argentina partial recovery.
Europe (UPL Corp)▬ –1%Fungicide sales normalizing after wet season last year; sustained growth in Germany, Italy, Spain, France; Turkey impacted by early frost.

U.S. Tariffs: The Fluid Risk Inside the Guidance

Mike Frank: "But if that changes, whether it's from competitors in China or from our own imports from India, then the whole dynamic in the market changes. So, it's very fluid, which I think we want to be cautious about putting a number out there."

Strategic Optionality: Platforms, Portfolio, and the Next Cycle


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth4% to 8% growth vs last yearFY26
EBITDA growth12% to 16% growth vs last year (raised from 10–14%)FY26
Net leverage1.6x to 1.8x net debt-to-EBITDABy FY26 year-end
DeleveragingShort-to-medium-term priority to deleverage balance sheet18–24 months
New product revenueSurpass $130 mn from new product launchesFY26
SUPERFORM non-agchem mixSuper Specialty to reach 30–35% of SUPERFORM business share24–36 months
Associates/JVs profitabilityTarget aggregate positive contributionNext year (FY27)
U.S. tariff impactCurrent duty structure baked into guidance; no material change to financial outcome expectedFY26, conditional on no tariff change

Key Metrics

MetricQ2 FY26
Revenue₹12,019 cr, +8% YoY; +7% volume, +3% FX, partially offset by pricing pressure
Contribution margin~42%, +420 bps YoY; improved product mix, higher capacity utilization, lower input costs
EBITDA₹2,205 cr, +40% YoY
EBITDA margin18.3%, +410 bps YoY
Profit before tax₹784 cr, up by over ₹1,200 cr YoY
Net finance costs₹518 cr, down from ₹847 cr YoY; debt prepayment, lower SOFR, ratings upgrade benefit
PATMI₹553 cr, up by ~₹1,000 cr YoY
Operational PATMI₹411 cr, up ₹845 cr from negative ₹434 cr YoY
Revenue growth guidance (FY26)4% to 8% (upgraded)
EBITDA growth guidance (FY26)12% to 16% (upgraded from 10%–14%)
Net debt₹23,802 cr (~$2.7 bn), down ₹3,729 cr ($605 mn) YoY; up vs Mar '25 due to $400 mn perpetual bond redemption and seasonal working capital
Net debt-to-EBITDA2.7x, improved from 5.4x YoY; Mar '25 was 1.7x (2.1x adjusted for perpetual bonds)
Net working capital days118 days, improved by 5 days YoY
UPL Corp revenue growth+12% YoY, volume-led
UPL Corp contribution margin35.1%, +400 bps YoY
UPL Corp EBITDA growth+69% YoY, margin expansion of nearly 500 bps
Advanta revenue growth+26% YoY; seeds volume +14%
Advanta EBITDA growth+57% YoY
UPL SAS revenue growth–10% YoY; unfavorable weather
UPL SAS EBITDA margin22.7%, +270 bps YoY; absolute EBITDA +2%
SUPERFORM revenueSteady vs last year; Super Specialty Chemicals +18%
Non-agchem revenue share~25%, up from 20% in Q2 last year
UPL Corp new product launch revenue target (FY26)At least $130 mn, expected to over-deliver
Brazil order bookUp ~20% vs same time last year